This story has been updated to include additional details about 10x Genomics’ legal proceedings with Illumina and Spatial Genomics.
10x Genomics officials touted the beginning of the company’s Atera era, even as the new spatial platform rollout dragged down instrument sales in the third quarter.
“The biggest highlight of the quarter was the start of commercial shipments of Atera,” 10x CEO and Cofounder Serge Saxonov said Nov. 5. “Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers’ hands.”
“Nearly all of the world’s top 20 biopharma companies have now purchased Atera systems or services,” from 10x, he added on a conference call with investors following the release of results.
The company is ramping production and now expects to ship approximately 50 Atera instruments by year end, up from a previous expectation of approximately 40, 10x CFO Adam Taich said.
That said, 10x’s instrument revenue in Q3 fell to $6.9 million from $12.0 million in Q3 2025, driven by a 56 percent decline in Spatial instruments, which dropped to $3.1 million from $7.1 million. “As anticipated, the decline in spatial instruments reflects customers moderating purchases of our Visium and Xenium products in anticipation of Atera,” Taich said. Single-cell instrument revenue fell to $3.8 million from $4.9 million.
Total third-quarter revenue was $150.7 million, up 1 percent from $149.0 million a year ago, beating the consensus Wall Street estimate of $147.9 million. Consumables revenue grew 5 percent year over year to $134.3 million, offsetting the decline in instrument revenue.
Consumables revenue was driven by spatial consumables revenue of $41.2 million, up 16 percent from $35.4 million a year ago, while single-cell consumables revenue was roughly flat at $93.1 million.
Services revenue was $9.0 million, up from $8.1 million.
In a Nov. 6 filing with the US Securities and Exchange Commission, 10x noted that it has expanded its single-cell technology patent infringement lawsuit to include US Patent No. 12,686,949, titled “Systems and methods for transfer of reagents between droplets.” The patent was issued to 10x July 21.
In October, 10x filed a countersuit against Spatial Genomics alleging that the company’s GenePS products infringe US Patent Nos. 11,293,051, 11,293,052, 11,566,277, and 12,618,099. It also asked the court to declare non-infringement and to invalidate the patents held by Spatial Genomics.
10x’s net loss for Q3 was $19.4 million, or $0.15 per share, compared with a net loss of $27.5 million, or $0.22 per share, in Q3 2025, beating the consensus Wall Street estimate of $0.26 loss per share.
R&D expense was $52.9 million, down from $57.2 million, and SG&A was $76.1 million, roughly flat from a year ago.
The company ended the quarter with $575.7 million in cash, cash equivalents, and marketable securities.
For the full year, 10x Genomics raised its revenue guidance to between $625 million and $635 million, from a prior range of $610 million to $630 million. Excluding non-recurring patent settlement licensing revenue in both years, the guidance implies growth of 4 percent to 6 percent over full-year 2025.